MARKET

KURA

KURA

Kura Oncology Inc
NASDAQ
20.25
+0.66
+3.37%
After Hours: 19.80 -0.45 -2.22% 19:50 02/23 EST
OPEN
19.71
PREV CLOSE
19.59
HIGH
20.69
LOW
19.58
VOLUME
572.57K
TURNOVER
0
52 WEEK HIGH
22.92
52 WEEK LOW
7.41
MARKET CAP
1.54B
P/E (TTM)
-10.0297
1D
5D
1M
3M
1Y
5Y
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
Kura Oncology, Inc. Will report fourth quarter and full year 2023 financial results after the close of U.S. Financial markets on February 27, 2024. The company will host a webcast and conference call to discuss the financial results. Kura is a clinical-stage biopharmaceutical company.
Barchart · 4d ago
Weekly Report: what happened at KURA last week (0212-0216)?
Weekly Report · 5d ago
Implied XBI Analyst Target Price: $136
NASDAQ · 02/15 12:56
Weekly Report: what happened at KURA last week (0205-0209)?
Weekly Report · 02/12 09:18
Kura Oncology files to sell 8.7M shares for its holders
Seeking Alpha · 02/09 22:44
Weekly Report: what happened at KURA last week (0129-0202)?
Weekly Report · 02/05 09:19
3 Best Stocks to Buy Now, 2/1/2024, According to Top Analysts 
TipRanks · 02/01 11:01
Positive Clinical Trial Results and Strategic Positioning Prompt Buy Rating and Price Target Increase for Kura Oncology
TipRanks · 02/01 05:05
More
About KURA
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of medicines for the treatment of cancer. The Company’s pipeline consists of small molecule product candidates that target cancer signaling pathways. The Company’s products candidate includes Ziftomenib, Tipifarnib, and KO-2806. The Ziftomenib is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene for the treatment of genetically defined acute myeloid leukemia (AML) patients. Tipifarnib is a potent, selective and orally bioavailable inhibitor of farnesyl transferase. KO-2806, is a next generation farnesyl transferase inhibitor (FTI), which it demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.

Webull offers Kura Oncology Inc stock information, including NASDAQ: KURA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KURA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KURA stock methods without spending real money on the virtual paper trading platform.